Atropine, a non-selective mAChR antagonist, has been shown to reduce the permeability of colon tissue in patients with ulcerative colitis and also further diminish histamine release and disrupt the interactions between mast cells corticotropin-releasing factor (CRF), and eosinophils in the mucosal barrier (307). OXO-M, a stable agonist of mAChR, and physostigmine, an AChE inhibitor, suppress histamine release (308). The gene discussed is CRH; the disease is ulcerative colitis.